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ESSAY
Why Some People Prefer Pickle Juice:
The Research of Dr. Richard P. Lifton
Peter M. Gayed
Yale University School of Medicine
In this essay, the author interviews Dr. Richard P. Lifton and examines the use of genomics
throughout his studies on the molecular pathophysiology of hypertensive and hypotensive
diseases. To date, Dr. Lifton has identified 10 different gene mutations that result in severe
hypertension and another 10 that result in severe hypotension.
Dr. Richard Lifton has seen patients
who crave nothing more than pickle juice.
“Another favorite snack is a salted lemon,”
reports Lifton, a Howard Hughes Medical
Investigator and chairman of the Depart-
ment of Genetics at Yale. His professional
career has been devoted to understanding
the complexities governing salt retention
and blood pressure, in which dietary prefer-
ences play a role. So far, Lifton counts 10
different genes and gene mutations that re-
sult in severe hypertension and another 10
that result in severe hypotension.
“Examining the extremes has revealed
a lot about the way our bodies regulate
blood pressure,” explains Lifton. Remark-
ably, these genes and their products all con-
verge on a single, powerful regulator of
blood pressure: renal salt retention. When
the kidneys are unable to excrete salt, water
is retained in the blood. “When too much
water is retained,” Lifton says, “blood pres-
sure goes up.” The converse is also true:
When too much salt is excreted in the urine,
water is lost, and the result is hypotension.
The chronically hypotensive body tries to
compensate in many ways, and one of
those ways is manifested by a craving for
salty products — and what better than
pickle juice?
The idea that the body might respond
to hypotension by increasing its salt intake
made good sense and was supported by re-
ports that the most hypotensive members of
an affected family also ingested the most
salt. What remained unclear to scientists
and clinicians, however, was the primary
organ responsible for salt retention and salt
wasting. “To address this problem,” Lifton
wrote in a 2002 review, “our group has
taken a genetic approach to the understand-
ing of hypertension in humans, using the
paradigm of positional cloning,” which re-
lies on knowing the approximate location
of a gene thought to be involved with a par-
ticular disease phenotype [1].
During the lab’s many chromosomal
walks, Lifton and his colleagues have re-
vealed the molecular pathophysiology of an
impressive number of diseases affecting salt
†Abbreviations: PHA, pseudohypoaldosteronism; ENaC, epithelial sodium channel; GRA,
glucocorticoid-remediable aldosteronism; SSCP, single-strand conformational polymor-
phism; MR, mineralocorticoid receptor.regulation.Amongthemaretwoformsoftype
I pseudohypoaldosteronism, Gitelman’s syn-
drome,Bartter’ssyndrome,glucocorticoid-re-
mediablealdosteronism,Liddlesyndrome,and
pregnancy-induced hypertension (the mecha-
nism of which, ironically, was characterized
whilestudyinganadolescentboywhosuffered
from significantly elevated blood pressure).
The last three of these diseases all cause hy-
pertension,anduntilrecently,physicianscould
do little more than haphazardly prescribe any
number of 70 antihypertensive drugs. Using
genomic methods and data, however, Lifton
and his colleagues more precisely have de-
scribed the distinct and varied genetic causes
of hypertension in several diseases.
Previous to 1980, it only would have
beenpossibletoidentifydiseasegenesifsuch
genesencodedproteinproductsthatcouldbe
purified[2].Onceisolated,fragmentsofpro-
teins were subjected to amino acid sequenc-
ing. Scientists then could construct several
oligonucleotidesthatcorrespondedtoallpos-
sible codon permutations of the amino acid
sequence. The batch of synthesized oligonu-
cleotides then could be used to screen a li-
braryofexpressedgenes(cDNA)inhopesof
identifying the gene of interest.
Now scientists like Lifton use markers
unique to a monogenic disease to locate,
clone, and study a disease gene. Genetic
markersthemselves firstcan beidentified by
collecting tissue samples from healthy and
afflicted family members and then analyzing
thosesamplesforspecificsequencepatterns,
such as single nucleotide polymorphisms.
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Figure 1. The accepted genetic map for the region associated with pseudohypoaldostero-
nism type 1. (From the NCBI Map Viewer, chromosomal region 4q31.1)Markers in proximity to a disease gene are
inherited with it, while distant markers show
weakornoco-inheritancewiththegene.Ge-
netic maps display this information as repre-
sentations of chromosomes, their genes, and
the relative distances between specific gene
loci (Figure 1). Presumably, affected mem-
bersofafamilysharethesamemutationand,
thus,exhibitasharedgeneticpatternthatcan
be elucidated by sequencing methods. Using
sequenced DNA fragments, geneticists can
search the Human Genome Project to iden-
tify and home in on candidate regions likely
to harbor the disease gene of interest.
In 1996, for example, the Lifton lab
published a study in which it used the
known sequence of a suspected sodium
channel to identify genotypic variations
among healthy individuals and individuals
suffering from pseudohypoaldosteronism
(PHA†) type 1. PHAis a potentially fatal dis-
ease marked by profound hypotension de-
spite abnormally high levels of circulating
aldosterone,a steroid hormone that normally
increases blood pressure [6].As Lifton pre-
dicted, affected patients were found to be
homozygous for a mutation that results in
the absence of the epithelial sodium channel
(ENaC), the primary channel by which the
kidney reabsorbs sodium.
Inanotherstudy,Liftonexaminedgluco-
corticoid-remediable aldosteronism (GRA),
which led to the discovery of a novel protein
caused by the fusion of two separate genes,
one encoding aldosterone synthase and the
other encoding 11-beta hydroxylase (Figure
2).InGRA,theresultantchimericproteinex-
hibitsconstitutivealdosteronesynthaseactiv-
ity and, consequently, causes overproduction
of aldosterone, leading to hypertension [3].
Lifton’s group used a kindred to establish
complete linkage to the 11-beta hydroxylase
locus.Againexploitingknowngenomicdata,
thegroupconstructedvariousgenefragments
to demonstrate the existence of the fusion
proteinbysingle-strandconformationalpoly-
morphism (SSCP). In SSCP, one strand of
DNAis amplified and run on a gel; differing
secondary structures, due to various muta-
tions, cause different bands to appear, which
subsequently can be sequenced.
In contrast to GRA, Liddle syndrome is
marked clinically by hypertension in the ab-
sence of elevated aldosterone levels. In its
study of Liddle syndrome, the Lifton group
mapped the phenotype to the gamma-ENaC
gene subunit and sequenced it to confirm a
suspected premature-stop mutation, distinct
from the mutation observed in PHApatients
[4]. The group analyzed a series of missense
mutations in an oocyte system to confirm the
role of this mutation in the pathogenesis of
Liddle syndrome. The mutation, the group
explains, prevents the channel’s clearance
fromthecellsurfacebycausingtruncationof
the signal sequence that allows for ubiquitin-
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Figure 2. Schematic description of the gene fusion event which results in the constitutive
production of the hormone aldosterone. (Courtesy of Dr. Richard P. Lifton)mediated degradation (Figure 3). The pro-
longedpresenceofENaCresultsinenhanced
sodium reabsorption and hypertension.
Oneofthemorerecentandsurprisingdis-
coveries of the Lifton lab, however, came in
2002whenaresequencingofgenesinvolvedin
the salt-retaining pathway revealed a mutation
inthemineralocorticoidreceptor(MR)ofa15-
year-oldhypertensiveboy[5].Normally,bind-
ing of aldosterone to MR causes increased salt
reabsorptionbyenhancingtheactivityofENaC.
However,themutation,whichreplacesasingle
serineresiduewithleucine,causesthereceptor
tobepartiallyactivatedintheabsenceofaldos-
terone. More interestingly, however, is that the
mutation enhances the receptor’s sensitivity to
progesteroneandcompletelyinvertstherolethe
steroid has on the receptor; that is, in the pres-
enceofthemutation,progesterone,whichusu-
ally acts as an antagonist, becomes a potent
agonist. Considering that progesterone levels
canincrease100-foldduringgestation,thisfind-
ing suggests the MR mutation also may be re-
sponsible for the severe pregnancy-induced
hypertensionobservedinsomewomen.Indeed,
inLifton’sstudy,twofemalecarriersofthemu-
tantallelehadmultiplehypertensivecomplica-
tionsduringeachoftheirpregnancies[6].
Lifton also has demonstrated that salt-
wasting defects, such as those seen in Gitel-
man’s syndrome, result in lowered blood
pressure. In a 2001 investigation, the Lifton
lab studied individuals who carried zero,
one, or two copies of a mutant gene encod-
ing a sodium-chloride cotransporter in order
to ascertain its influence on blood pressure
[6]. Mutations were identified using SSCP.
The group found that homozygous mutant
individuals had diastolic blood pressures
about 8 mm Hg lower than their wild-type
and heterozygous kindred.Although no sig-
nificant blood pressure differences existed
between the heterozygous group and the
wild-type group, members of the former
consumed significantly more salt in their
diet, which Lifton explains as a compensa-
tory dietary preference counterbalances the
mild salt-wasting defect.
For as much as Lifton has accom-
plished, the problem of hypertension re-
mains a difficult one because the majority of
hypertensive patients do not have a mutation
that leads to profound physiological defects.
Rather, it is more often the case these pa-
tients are afflicted by subtle and varied
genotypic patterns that give rise to a set of
heterogeneous disease states we have
grossly named “chronic hypertension.”
“If there are many genes that influence
[chronic hypertension] by a common path-
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Figure 3. Luminal surface of distal nephron in healthy individual (top half) and patient with
Liddle syndrome (bottom half). In Liddle syndrome, the signal sequence known as PPPXY
is lost, which impairs the normal clearance of ENaC via clathrin-coated endocytosis.
(Courtesy of Dr. Richard P. Lifton)way,” Lifton says, “one could explain vari-
ation of disease risk within the population.”
Lifton’s use of genomics has changed the
very way he foresees geneticists applying
the technology: “These [variations] can only
be found by resequencing genes, pathways,
or genomes. In coming years, we expect
technologies for resequencing the human
genome to plummet. Initial efforts will in-
stead focus on resequencing a small number
of high priority genes in thousands of sub-
jects. This will evolve next to resequencing
all the genes and conserved elements, which
constitute only a few percent of the genome.
Finally, we will begin resequencing entire
genomes in large cohorts.”
Of course, Lifton is not merely forecast-
ing the future of genomics — he is already
living it. “We have recently completed such
a resequencing study of salt-handling genes
in the Framingham Heart Study cohort,” he
announces. The results, no doubt, will lead
to valuable discoveries. Until Lifton figures
things out, however, some of us will have to
go on drinking pickle juice.
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